...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis
【24h】

The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis

机译：术后放射治疗对可重演阶段III-N2非小细胞肺癌患者存活的影响：系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the potentially resectable cases of stage III-N2 non-small-cell lung cancer (NSCLC), the optimal post-operative treatment regimen for these patients is uncertain and post-operative radiation therapy (PORT) with chemotherapy is typically recommended. Our aim was to reassess the data of PORT on overall survival (OS) and disease-free survival (DFS) in stage III-N2 NSCLC, in order to figure out whether PORT might lead to a moderate improvement in local control and survival besides resection and adjuvant chemotherapy. A comprehensive search strategy was performed in EMBASE, PubMed, and Cochrane Library for relevant studies comparing PORT combined with adjuvant chemotherapy or adjuvant chemotherapy alone on OS and DFS in resectable stage III-N2 NSCLC. Data were extracted to estimate the effects of PORT on OS and DFS. Eleven studies with 8,928 patients were included. This meta-analysis demonstrated a trend in improving OS associated with the use of PORT (HR=0.88; 95% CI, 0.76 to 1.03; p=0.11) and a significantly difference of effect on DFS associated with the use of PORT (HR=0.78; 95% CI, 0.66 to 0.92; p=0.003). In a subgroup analysis on Caucasian patients, there was a statistically significant benefit (HR=0.88; 95% CI, 0.81 to 0.96; p=0.003) on OS for PORT. Our findings demonstrate that in the postoperative treatment for patients with stage III-N2 NSCLC, PORT is associated with improved OS and leads to a significantly increased DFS.
机译：在III-N2期非小细胞肺癌（NSCLC）的可能性可重置案例中，这些患者的最佳术后治疗方案通常建议使用化疗的不确定和术后放射治疗（端口）。我们的目标是重新评估III-N2 NSCLC中总存活（OS）和无病生存（DFS）的港口数据，以弄清楚港口是否可能导致局部控制和存活的中度改善，除了切除和佐剂化疗。在Embase，Pubmed和Cochrane库中进行了一个综合搜索策略，用于相关研究比较端口与辅助化疗或单独的辅助化疗，在可重置阶段III-N2NSCLC中单独对OS和DFS进行佐剂化疗。提取数据以估计端口对OS和DFS的影响。包括8,928名患者的11项研究。该荟萃分析证明了改进与港口相关联的OS的趋势（HR = 0.88; 95％CI，0.76至1.03; P = 0.11）以及对与使用端口相关的DF的影响显着差异（HR = 0.78; 95％CI，0.66至0.92; p = 0.003）。在高加索患者的亚组分析中，在OS的统计学上显着的益处（HR = 0.88; 95％CI，0.81至0.96; p = 0.003）。我们的研究结果表明，在III-N2 NSCLC患者的术后治疗中，端口与改善的OS相关，并导致显着增加的DFS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号